Notably, subgroup analysis excluding Huang et al. decreased the heterogeneity I2 and significantly associated HER2+ breast cancer patients with better pCR outcome when treated with TP (OR 2.36; 95% CI 1.07–5.20; p=0.03). This evidence concerns the gene ERBB2 and breast carcinoma.